Page last updated: 2024-09-05

lapatinib and ag-879

lapatinib has been researched along with ag-879 in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (ag-879)	Trials (ag-879)	Recent Studies (post-2010) (ag-879)
1,919	305	1,442	57	0	21

Protein Interaction Comparison

Protein	Taxonomy	ag-879 (IC50)
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	1
High affinity nerve growth factor receptor	Homo sapiens (human)	10
Ephrin type-A receptor 3	Mus musculus (house mouse)	0.005

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brattain, MG; Conway, AN; Hauser, J; Hu, YP; Humphrey, L; Li, S; Vinci, MA; Wang, J; Willson, JK; Zborowska, E; Zhou, Y	1
Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z	1

Other Studies

2 other study(ies) available for lapatinib and ag-879

Article	Year
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer research, 2006, Jan-01, Volume: 66, Issue:1 Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays	2006
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins	2010

Article

Year

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Cancer research, 2006, Jan-01, Volume: 66, Issue:1

Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays

2006

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins

2010